News

To receive future news releases direct to your inbox, subscribe by emailing ir@resverlogix.com.

Historical news and financial information can also be found at www.sedar.com under the Company’s profile.



Print Version

Resverlogix to Hold BETonMACE Conference Call and Webcast on November 18, 2019

The Presentation of Additional BETonMACE Results to Supplement AHA Late Breaking Science Session held on November 16, 2019

CALGARY, Alberta, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX: RVX) today announces that it has scheduled a conference call and webcast to supplement the presentation of BETonMACE results to be made during the American Heart Association’s (“AHA”) annual conference. As previously reported, the primary results of the BETonMACE trial will be presented on November 16th during the AHA’s Scientific Sessions 2019 held in Philadelphia, Pennsylvania; additional details can be found HERE. Following the AHA presentation, the Company will host a conference call and webcast currently scheduled for 8:30 am ET on November 18th, 2019.

For those wishing to join the November 18th event, it is highly recommended to access the webcast over the Internet using the following LINK. A replay of the webcast (using the same link provided) will be available for one month following the conclusion of the event.

If dialing in by phone, dial 1-800-319-4610 (within Canada / USA) or +1-604-638-5340 (International Toll). Callers should dial-in at least 10 min prior to the scheduled start time. A teleconference replay will be available for two weeks following the conclusion of the event and can be accessed by dialing 1-800-319-6413 (within Canada / USA) or +1-604-638-9010 (International Toll) and using the replay access code: 3856#.

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra-terminal) inhibitor. BET inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases, while maintaining a well described safety profile.

Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX).

Follow us on:

For further information please contact:

Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
Or visit our website: www.resverlogix.com

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to a BETonMACE conference call and webcast and the potential role of apabetalone in the treatment of high-risk cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease treated with hemodialysis, neurodegenerative disease, Fabry disease, peripheral artery disease and other orphan diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Back to News